Diagnostic of Heart Failure

Abstract

The invention relates to a method for classifying a patient at risk for heart failure, wherein said method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from said patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.

1 . A method for classifying a patient at risk for heart failure, wherein said method comprises the steps of:
 i. measuring the concentration of IGFBP2 in a sample obtained from said patient, and   ii. comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.   
     
     
         2 . A method for diagnosis of heart failure in a patient comprising:
 i. determining the concentration of IGFBP2 in a sample obtained from said patient; and   ii. comparing said concentration to a control value.   
     
     
         3 . The method according to  claim 1  wherein the heart failure is an asymptomatic heart failure, a chronic heart failure or an acute heart failure. 
     
     
         4 . The method according to  claim 1 , wherein said sample is selected in the group consisting of plasma and urine sample. 
     
     
         5 . The method according to  claim 1 , wherein the concentration of IGFBP2 is measured by quantifying the level of IGFBP2 protein in the sample. 
     
     
         6 . The method according to  claim 5 , wherein the quantification of the level of IGFBP2 protein is performed by using a set of antibodies directed against IGFBP2. 
     
     
         7 . The method according to  claim 5 , wherein the quantification of the level of IGFBP2 protein is performed by ELISA. 
     
     
         8 . The method according to  claim 5 , wherein the quantification of the level of IGFBP2 protein is performed by capillary electrophoresis-mass spectroscopy technique. 
     
     
         9 . The method according to  claim 2  wherein the heart failure is an asymptomatic heart failure, a chronic heart failure or an acute heart failure. 
     
     
         10 . The method according to  claim 2 , wherein said sample is selected in the group consisting of plasma and urine sample. 
     
     
         11 . The method according to  claim 2 , wherein the concentration of IGFBP2 is measured by quantifying the level of IGFBP2 protein in the sample. 
     
     
         12 . The method according to  claim 11 , wherein the quantification of the level of IGFBP2 protein is performed by using a set of antibodies directed against IGFBP2. 
     
     
         13 . The method according to  claim 11 , wherein the quantification of the level of IGFBP2 protein is performed by ELISA. 
     
     
         14 . The method according to  claim 11 , wherein the quantification of the level of IGFBP2 protein is performed by capillary electrophoresis-mass spectroscopy technique.